Literature DB >> 26626203

Clinical outcomes of combined necrotizing pancreatitis versus extrapancreatic necrosis alone.

Mingjun Wang1, Ailin Wei1, Qiang Guo1, Zhaoda Zhang1, Huimin Lu1, Ang Li1, Weiming Hu2.   

Abstract

INTRODUCTION: Extrapancreatic necrosis (EPN) alone, i.e., in the absence of pancreatic parenchyma necrosis has gradually come to be regarded as a separate entity of acute necrotizing pancreatitis (ANP). However, data regarding the prognostic significance of EPN are quite limited, and the outcomes of interventions for patients with EPN alone are not well elucidated. The aim of this study was to explore the differences in the outcomes of patients with EPN alone and patients with both the pancreatic parenchyma and extrapancreatic necrosis (combined necrosis).
METHODS: From January 2009 to December 2013, a total of 334 patients with ANP who had received interventions in the West China Hospital in China were included. Based on the extent of necrosis as assessed with contrast-enhanced CT, the patients were divided into Group 1 (n = 285) in which the necrosis involved both the pancreatic parenchyma and extrapancreatic tissues (combined necrosis) and Group 2 (n = 49) in which the necrosis involved only the extrapancreatic tissues. Additionally, Group 3 included 443 patients with interstitial pancreatitis who were also included in the analyses. The demographic characteristics, support treatment information, organ failure information, infection necrosis, persistent systemic inflammatory response syndrome (SIRS) in the first week of onset, CT severity index, and intervention types, as well as the postoperative stay lengths, ICU utility, and complications were collected and compared.
RESULTS: Compared with the patients in Group 1, the patients in Group 2 suffered less persistent SIRS in the first week of onset (12/24.5% vs. 145/50.9%; P < 0.05), less persistent organ failure (6/12.2% vs. 95/33.3%; P < 0.05), less persistent multiple organ failure (3/6.1% vs. 67/23.5%; P < 0.05), and less bacteremia (5/10.2% vs. 107/37.5%; P < 0.001). The intervention types were significantly different between the two groups (P < 0.001); initial open necrosectomy was performed in 174/61.6% and 8/16.3% of the patients in Groups 1 and 2, respectively, and initial percutaneous catheter drainage (PCD) was performed in 73/25.6% and 29/59.2% of the patients in the two respective groups. Second open necrosectomies following PCD were required in 61/83.5% and 9/31.0% of the patients in Groups 1 and 2, respectively (P < 0.001). A greater number of patients in Group 1 were diagnosed with infected necrosis (204/71.6% vs. 10/20.4%; P < 0.001) and had to be sent to the ICU for further postoperative care (221/77.5% vs. 23/46.9%; P < 0.001). The postoperative stay was longer for Group 1 (median: 43.0 vs. 26.5 days; P < 0.001). Residual necrotic tissue or abscess was the most common postoperative complication in both groups. The mortality was higher in Group 1 (52/18.2% vs. 1/2.1%; P < 0.05). Compared with the patients in Group 2, the patients with interstitial pancreatitis exhibited milder courses and better outcomes. Subgroup comparisons with Group 1 indicated that early multiple organ failure was significantly associated with higher mortality.
CONCLUSION: The patients with EPN alone exhibited significantly better prognoses than those with combined necrosis, and EPN alone should be regarded as a separate group of acute necrotizing pancreatitis. Open necrosectomy can be avoided in the majority of patients with EPN alone, who receive PCD as the initial first intervention.
Copyright © 2015 IAP and EPC. Published by Elsevier India Pvt Ltd. All rights reserved.

Entities:  

Keywords:  Acute necrotizing pancreatitis; Complications; Extrapancreatic necrosis; Multiple organ failure; Pancreatic parenchyma necrosis; Prognosis

Mesh:

Year:  2015        PMID: 26626203     DOI: 10.1016/j.pan.2015.10.010

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  7 in total

1.  Revised Atlanta classification for CT pancreatic and peripancreatic collections in the first month of acute pancreatitis: interobserver agreement.

Authors:  Neesmah Badat; Ingrid Millet; Lucie Corno; Wassef Khaled; Isabelle Boulay-Coletta; Marc Zins
Journal:  Eur Radiol       Date:  2019-01-10       Impact factor: 5.315

2.  Infectious Complications of Acute Pancreatitis Is Associated with Peripheral Blood Phagocyte Functional Exhaustion.

Authors:  Yaroslav M Susak; Olexandr O Dirda; Olexandr G Fedorchuk; Olekcandr A Tkachenko; Larysa M Skivka
Journal:  Dig Dis Sci       Date:  2020-03-13       Impact factor: 3.199

3.  Prognostic significance of differentiating necrosis from fluid collection on endoscopic ultrasound in patients with presumed isolated extrapancreatic necrosis.

Authors:  Surinder S Rana; Puneet Chhabra; Ravi Sharma; Vishal Sharma; Rajesh Gupta; Deepak K Bhasin
Journal:  Ann Gastroenterol       Date:  2016-11-14

4.  Impact of the site of necrosis on outcome of acute pancreatitis.

Authors:  Narendra Dhaka; Saroj K Sinha; Jayanta Samanta; Vikas Gupta; Thakur Deen Yadav; Ajay Gulati; Rakesh Kochhar
Journal:  JGH Open       Date:  2018-09-24

5.  Large triglyceride-rich lipoproteins in hypertriglyceridemia are associated with the severity of acute pancreatitis in experimental mice.

Authors:  Yue Zhang; Wenhua He; Cong He; Jianhua Wan; Xiao Lin; Xi Zheng; Lei Li; Xueyang Li; Xiaoyu Yang; Bingjun Yu; Xunde Xian; Yin Zhu; Yuhui Wang; George Liu; Nonghua Lu
Journal:  Cell Death Dis       Date:  2019-09-30       Impact factor: 8.469

6.  Malignant Hypertension Complicated with Necrotizing Pancreatitis After Starting Treatment: A Case Report.

Authors:  Shun Yoshida; Shotaro Takakuwa; Hiromi Kihira; Yasuhide Nishio; Manabu Haneda
Journal:  Am J Case Rep       Date:  2022-02-28

Review 7.  Direct Endoscopic Necrosectomy: Timing and Technique.

Authors:  Sergio Pinto; Saverio Bellizzi; Roberta Badas; Maria Laura Canfora; Erica Loddo; Simone Spada; Kareem Khalaf; Alessandro Fugazza; Silvio Bergamini
Journal:  Medicina (Kaunas)       Date:  2021-11-28       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.